VIGL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIGL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-23), Vigil Neuroscience's share price is $3.61. Vigil Neuroscience's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.80. Hence, Vigil Neuroscience's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Vigil Neuroscience's Price-to-Free-Cash-Flow or its related term are showing as below:
Vigil Neuroscience's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.55. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.80.
The historical data trend for Vigil Neuroscience's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigil Neuroscience Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Price-to-Free-Cash-Flow | - | - | - | - |
Vigil Neuroscience Quarterly Data | |||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Vigil Neuroscience's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vigil Neuroscience's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Vigil Neuroscience's Price-to-Free-Cash-Flow falls into.
Vigil Neuroscience's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 3.61 | / | -1.796 | |
= | N/A |
Vigil Neuroscience's Share Price of today is $3.61.
Vigil Neuroscience's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Vigil Neuroscience (NAS:VIGL) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Vigil Neuroscience's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Ivana Magovcevic-liebisch | director, officer: President and CEO | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Christopher Silber | officer: Chief Medical Officer | C/O VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472 |
Budd Haeberlein Samantha L. | director | VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472 |
Gray David L. F. | officer: Chief Science Officer | VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472 |
Spyridon Papapetropoulos | officer: Chief Medical Officer | C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Clay Thorp | director | C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701 |
Evan Thackaberry | officer: SVP, Head of Early Development | VIGIL NEUROSCIENCE, INC., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Jennifer Lynn Ziolkowski | officer: Chief Financial Officer | C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139 |
Christopher Verni | officer: General Counsel | VIGIL NEUROSCIENCE, INC., 1 BROADWAY, 7TH FLOOR, SUITE 07-300, CAMBRIDGE MA 02142 |
Mary Thistle | director | C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142 |
Vida Ventures Gp Iii, L.l.c. | 10 percent owner | 455 MARKET STREET, SUITE 1420, SAN FRANCISCO CA 94105 |
Northpond Ventures Gp, Llc | 10 percent owner | 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814 |
Stefan Vitorovic | director | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Bruce Booth | director | 890 WINTER STREET, SUITE 320, WALTHAM MA 02451 |
From GuruFocus
By sperokesalga sperokesalga • 05-08-2023
By sperokesalga sperokesalga • 05-09-2023
By PurpleRose PurpleRose • 08-12-2022
By Value_Insider Value_Insider • 11-28-2022
By Marketwired • 08-08-2023
By Value_Insider Value_Insider • 12-14-2022
By Marketwired • 10-17-2023
By PurpleRose PurpleRose • 08-08-2022
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 08-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.